Mana Capital Acquisition (MAAQ) Competitors $0.38 -0.03 (-8.08%) As of 03/28/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock MAAQ vs. IPA, MTVA, HCWB, SPRB, FLGC, AFMD, IXHL, NERV, BCDA, and EGRXShould you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include ImmunoPrecise Antibodies (IPA), MetaVia (MTVA), HCW Biologics (HCWB), Spruce Biosciences (SPRB), Flora Growth (FLGC), Affimed (AFMD), Incannex Healthcare (IXHL), Minerva Neurosciences (NERV), BioCardia (BCDA), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry. Mana Capital Acquisition vs. ImmunoPrecise Antibodies MetaVia HCW Biologics Spruce Biosciences Flora Growth Affimed Incannex Healthcare Minerva Neurosciences BioCardia Eagle Pharmaceuticals Mana Capital Acquisition (NASDAQ:MAAQ) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap manufacturing companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends. Which has better earnings and valuation, MAAQ or IPA? Mana Capital Acquisition has higher earnings, but lower revenue than ImmunoPrecise Antibodies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMana Capital AcquisitionN/AN/AN/AN/AN/AImmunoPrecise Antibodies$24.07M0.47-$20.13M-$1.16-0.31 Do analysts rate MAAQ or IPA? ImmunoPrecise Antibodies has a consensus price target of $4.00, suggesting a potential upside of 995.89%. Given ImmunoPrecise Antibodies' stronger consensus rating and higher probable upside, analysts clearly believe ImmunoPrecise Antibodies is more favorable than Mana Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor MAAQ or IPA? ImmunoPrecise Antibodies received 12 more outperform votes than Mana Capital Acquisition when rated by MarketBeat users. However, 100.00% of users gave Mana Capital Acquisition an outperform vote while only 92.86% of users gave ImmunoPrecise Antibodies an outperform vote. CompanyUnderperformOutperformMana Capital AcquisitionOutperform Votes1100.00% Underperform VotesNo VotesImmunoPrecise AntibodiesOutperform Votes1392.86% Underperform Votes17.14% Is MAAQ or IPA more profitable? Mana Capital Acquisition has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -114.50%. Mana Capital Acquisition's return on equity of 0.00% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets Mana Capital AcquisitionN/A N/A N/A ImmunoPrecise Antibodies -114.50%-73.74%-42.68% Do insiders & institutionals have more ownership in MAAQ or IPA? 68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer MAAQ or IPA? In the previous week, ImmunoPrecise Antibodies had 10 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 10 mentions for ImmunoPrecise Antibodies and 0 mentions for Mana Capital Acquisition. ImmunoPrecise Antibodies' average media sentiment score of 0.02 beat Mana Capital Acquisition's score of 0.00 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the news media. Company Overall Sentiment Mana Capital Acquisition Neutral ImmunoPrecise Antibodies Neutral SummaryImmunoPrecise Antibodies beats Mana Capital Acquisition on 8 of the 13 factors compared between the two stocks. Remove Ads Get Mana Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAAQ vs. The Competition Export to ExcelMetricMana Capital AcquisitionIn Vitro, In Vivo Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$3.09M$3.09M$2.06B$7.79BDividend YieldN/AN/A2.68%4.05%P/E RatioN/AN/A23.5018.68Price / SalesN/AN/A71.9089.80Price / CashN/AN/AN/A34.64Price / BookN/AN/A1.994.12Net IncomeN/AN/A-$389.14M$247.10M7 Day Performance-15.60%-15.60%-2.62%-3.82%1 Month Performance-15.47%-15.47%-3.47%-6.61%1 Year Performance-73.25%-73.25%3.59%-1.67% Mana Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAAQMana Capital AcquisitionN/A$0.38-8.1%N/A-73.3%$3.09MN/A0.001High Trading VolumeIPAImmunoPrecise Antibodies2.2744 of 5 stars$0.44+3.0%$5.00+1,035.6%-75.2%$13.68M$24.07M-0.5680Earnings ReportAnalyst ForecastShort Interest ↑News CoverageMTVAMetaVia2.1526 of 5 stars$1.56-1.9%$12.00+669.2%N/A$13.50MN/A0.0010News CoverageHCWBHCW Biologics1.4217 of 5 stars$0.30+0.1%N/A-83.9%$13.47M$3.50M-0.3040Earnings ReportUpcoming EarningsSPRBSpruce Biosciences3.1867 of 5 stars$0.32-0.5%$2.50+687.4%-63.1%$13.11M$7.10M-0.3420Upcoming EarningsShort Interest ↓Positive NewsGap UpFLGCFlora Growth3.1702 of 5 stars$0.67-0.7%$5.00+647.4%-73.8%$13.00M$59.51M-0.51280Short Interest ↓Gap DownAFMDAffimed4.4204 of 5 stars$0.81-2.8%$13.50+1,577.0%-86.4%$12.96M$877,000.000.00200Analyst ForecastShort Interest ↓IXHLIncannex Healthcare0.9157 of 5 stars$0.71-1.5%N/A-81.2%$12.68M$98,000.00-0.513Positive NewsNERVMinerva Neurosciences3.8388 of 5 stars$1.81-2.9%$5.00+176.2%-34.1%$12.66MN/A-4.119BCDABioCardia2.8835 of 5 stars$2.68+5.1%$25.00+832.8%-58.4%$12.29M$71,000.00-0.6440Earnings ReportNews CoverageGap DownEGRXEagle PharmaceuticalsN/A$0.95-5.5%N/A-81.3%$12.27M$257.55M0.00100Analyst ForecastNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies IPA Alternatives MTVA Alternatives HCWB Alternatives SPRB Alternatives FLGC Alternatives AFMD Alternatives IXHL Alternatives NERV Alternatives BCDA Alternatives EGRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAAQ) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mana Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mana Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MAAQ Stock Free MAAQ Stock Alerts